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Abstract
Sphingosine kinase 1 (SphK1), a key enzyme responsible for phosphorylating sphingosine into sphingosine-1-
phosphate (S1P) has been shown to be expressed in monocytes and monocyte-derived peripheral macrophages.
This study demonstrates SphK1 immunoexpression in amoeboid microglial cells (AMC), a nascent monocyte-
derived brain macrophage in the corpus callosum of developing rat brain. SphK1 immunofluorescence expression,
which appeared to be weak in AMC in normal brain, was markedly induced by lipopolysaccharide (LPS) or hypoxia
treatment. Western blot analysis also showed increased expression level of SphK1 in the corpus callosum rich in
AMC after LPS treatment. Detection of SphK1 mRNA and its upregulation after LPS treatment was confirmed in
primary culture AMC by RT-PCR. Administration of N, N-dimethylsphingosine (DMS), a specific inhibitor of SphK1,
effectively reduced upregulated SphK1 immunoexpression in AMC both in vivo and in vitro. This was corroborated
by western blot which showed a decrease in SphK1 protein level of callosal tissue with DMS pretreatment.
Remarkably, LPS-induced upregulation of the transcription factor NFB was suppressed by DMS. We conclude that
SphK1 expression in AMC may be linked to regulation of proinflammatory cytokines via an NFB signaling
pathway.
Background
Sphingosine kinase (SphK) is an enzyme that phosphory-
lates sphingosine to sphingosine-1-phosphate (S1P). SphK
has two isoforms, SphK1 and SphK2, that have different
properties and subcellular localizations [1,2]. While much
has been reported on the expression and roles of SphK1 in
different cells and its participation in distinct biological
functions [1], the biological functions of SphK2 are not yet
clearly defined. This study focused on SphK1 in view of its
potential role in the central nervous system (CNS) [1].
SphK1 is mainly and abundantly expressed in cytosol of
hippocampal neurons, endothelial cells, cerebellar granule
cells and astrocytes of rat brain; and in cultured oligoden-
drocytes and murine BV2 cells [3-7]. SphK1 is also
expressed in other tissues including heart, lungs, and kid-
neys [8,9]. SphK1 overexpression enhances cell survival
and cell proliferation [10]. Studies of expression and func-
tions of SphK1 in several types of human cancer tissues
[11,12], primary human astrocytes [13], various glioblas-
toma cell lines [14,15], and cultured brain endothelial cells
[6] have shown that it may serve as a novel and useful
prognostic marker for astrocytoma and, furthermore, it
may play an important role during the development and
progression of neoplastic diseases [16,17]. Despite this,
however, there is only a modicum of information on the
role of SphK1 in the brain, especially in regard to its locali-
zation in microglia in vivo. This is particularly so in amoe-
boid microglial cells (AMC) in the developing brain,
which are considered to be the nascent brain macrophages
[18]. Indeed, as far as can be ascertained, expression of
S1P receptors has been reported in microglia only in cul-
ture [5,19]. In this connection, it is relevant to note that
SphK 1 is highly expressed in blood monocytes [20], the
precuror cells of AMC [18].
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We have reported recently that AMC, when challenged
with LPS or exposed to hypoxia, release large amounts of
inflammatory cytokines including TNF-a and IL-1b [21].
The production of TNF-a and IL-1b involves SphK1 in
LPS-activated monocytes/macrophages and BV2 cells
[5,22]. Interestingly, SphK1 is linked to TNF-a triggered
release of cytokines such as IL-1b and IL-6 [20], indicat-
ing its role in proinflammatory activities. Additionally, it
has been reported that SphK1 expression in human
endothelial cells and U87MG glioma cells may also be
regulated under hypoxic condition [23,24]. In the light of
the above, this study sought to determine if AMC in
postnatal rats express SphK1 and, if so, to determine how
it might be regulated during microglial activation
induced by LPS or hypoxia. To this end, blockade or
down-regulation of SphK1 by its specific inhibitor
namely, N, N-dimethylsphingosine, (DMS), could help to
unravel the functions of SphK1 [25]. The information is
important as AMC have been shown to be involved in
neuroinflammatory processes [26] that have been impli-
cated in the early stages of various neurodegenerative dis-
orders [27]. Hence, ascertaining SphK1 expression in
microglia in normal and under altered conditions could
lead to a better clarification of its specific role in
neuroinflammation.
Methods
Wistar rats of different age groups (1, 3, 5, 7, 14 and 21
days, and 1 month) were purchased from the Laboratory
Animal Centre, National University of Singapore. All
experiments were carried out in accordance with the
International Guiding Principles for Animal Research, as
adopted by the Institutional Animal Care and Use Com-
mittee, National University of Singapore. All efforts were
made to minimize pain and the number of rats used.
Normal postnatal rats
Wistar rats aged 1, 3, 5, 7, 14 and 21 days were used for
immunofluoresence studies (n = 3, at each age). The
rats were anesthetized with Nembutal (sodium pento-
barbital, 60 mg/kg) and perfused transcardially with
Ringer’s solution followed by 2% paraformaldehyde in
0.1 M phosphate buffer. Following perfusion, the brain
was removed, post-fixed in the same fixative and cryo-
protected in 30% sucrose for 24 h. Frozen sections at
30 μm were cut coronally through the forebrain with a
cryostat (Model CM 3050; Leica Instruments GmbH,
NUBLOCH, Germany) and mounted onto gelatin-coated
slides and stored at -20°C until use.
Injection of lipopolysaccharide
Fifty four 5-day-old rats were divided into 6 groups. In
each group (n = 9), 3 rats were used for immunofluore-
sence staining and 6 for reverse transcription polymerase
chain reactions (RT-PCR) and western blotting. In the
experimental groups, the rats were given an intraperito-
neal (i.p.) injection of 100 μL lipopolysaccharide (LPS)
(1 mg/kg; Cat. No. L2654, Sigma-Aldrich, MO, USA).
Three rats each were sacrificed at 30 min, 1 h and 6 h
after LPS injection; 9 rats receiving an equal volume of
saline served as matching controls. In another experi-
mental group receiving DMS and LPS treatments, the
rats were given an i.p. injection of 100 μl DMS (100 μM,
Cat. No.310500, Calbiochem, USA) followed by LPS
(3 mg/kg) injection 15 min later. For immunostaining,
the brain was removed and sectioned, and the tissue sec-
tions stored with the same procedure as described above.
For western blotting and quantitative RT-PCR analysis,
the brain was exposed and the cerebral hemispheres dis-
sected under deep anaesthesia. Fresh tissue samples of
the corpus callosum above the lateral ventricles were
carefully dissected and kept in liquid nitrogen until
further use.
Hypoxic exposure
Forty five rats, aged 5 days, were divided into 5 groups
(n = 9 each). Twenty seven rats were placed in a cham-
ber filled with a gas mixture of 5% oxygen and 95%
nitrogen (MCO18M; Sanyo Biomedical Electrical Co
Ltd, Tokyo, Japan) for 2 h. They were allowed to
recover in air and at room temperature for 15 min, 1 h
and 6 h before being sacrificed. In another experimental
group, the rats received DMS pretreatment followed by
hypoxia exposure 15 min later. Nine rats were given
firstly with an i.p. injection of 100 μl DMS (100 μM,
Cat. No.310500, Calbiochem, USA), followed by an
acute hypoxic exposure in an incubator for 2 h. Nine
rats kept outside of the chamber were used as normal
control. In each group, 3 rats were used for immuno-
fluorescence staining, with the remaining 6 rats used for
RT-PCR and western blotting analysis. Tissue sections
and fresh corpus callosum were removed for different
methods as described above.
Immunofluorescence staining
Tissue sections were rinsed in phosphate-buffered saline
(PBS) and then incubated in 5% normal goat serum
diluted in PBS for 1 h at room temperature. Following
removal of serum, tissue sections were incubated over-
night with a mixture of primary antibodies containing
OX-42 (1:300, mouse monoclonal IgG, Cat. No.
CBL1512, Chemicon, USA) and anti-SphK1 (1:100, rab-
bit polyclonal, Cat. No.sc-48825IgG, Santa Cruz, USA)
antibodies at room temperature. Some sections were
incubated with preimmune rabbit IgG (Cat. No. 17-615,
Millipore, USA) as isotypic controls. Sections from LPS
or DMS/LPS treated samples were also incubated with
OX-42 along with either anti-tumor necrosis factor-a
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(TNF-a), anti-interleukin-1b (IL-1b) (TNFa, rabbit poly-
clonal, Cat. No. AB1837P; IL-1b, rabbit polyclonal, Cat.
No. AB1832P, Chemicon, USA) or anti-NFB (1:200,
rabbit polyclonal, sc-109, Santa Cruz) antibodies. On the
next day, the sections were washed in PBS-Triton X 100
(TX). They were incubated with a mixture of secondary
antibody: FITC-conjugated goat anti-rabbit IgG (1:200,
Chemicon, USA) and Cy3-conjugated goat anti-mouse
IgG (1:200, Chemicon, USA) for 1 h. After washing in
PBS-TX, sections were stained with 4’, 6-diamidino-2-
phenylindole (DAPI, 1 μg/mL) for 2 min at room tem-
perature. They were then rinsed in PBS-TX and
mounted with a fluorescent mounting medium (DAKO
Cytomation, Glostrup, Denmark). Colocalization was
examined under a confocal microscope (LSM FV1000;
Olympus Company Pte. Ltd., Tokyo, Japan).
Western blot assay
Proteins were extracted from the frozen corpus callosum
of saline-, LPS- and DMS+LPS-injected rats using a pro-
tein extraction kit (Pierce Biotechnology Inc, IL, USA).
The concentration of protein was measured using
bovine serum albumin (Sigma-Aldrich, St Louis, MO,
USA) as a standard. Samples of supernatant containing
50 μg protein were heated at 95°C for 4 min and sepa-
rated in 10% sodium dodecyl sulfate-polyacrylamide
gels. The proteins were transferred to immobilon polyvi-
nylidene difluoride transfer membranes using a semi-dry
electrophoretic transfer cell (Bio-Rad, CA, USA). The
membranes were blocked with 5% non-fat dry milk in
Tris-buffered saline containing 0.1% Tween 20 (TBST)
for 1 h at room temperature. The membranes were
incubated with the primary antibody anti-Sphk1 (1:1000,
rabbit polyclonal IgG, Cat. No.sc-48825, Santa Cruz,
USA) at 4°C overnight with shaking. After thorough
washing in Tris buffered saline with Tween-20 (TBST),
the membranes were incubated with horseradish peroxi-
dase (HRP)-conjugated secondary antibody (1:5000, goat
anti-rabbit IgG, Cat. No. GF9501119, Pierce, USA) for 1
h at room temperature. The immunoproducts were
detected using a chemiluminescence detection system
according to the manufacturer’s instructions (Super-
signal West Pico Horseradish Peroxidase Detection Kit,
Pierce Biotechnology, IL, USA) and developed on a film.
The membranes were washed and stripped with
Western Blot Stripping Buffer (Prod #21059, Thermo,
USA). They were then incubated with primary antibody
anti-b-actin (1:10,000, mouse monoclonal, Sigma-
Aldrich, MO, USA) at 4°C overnight with shaking. After
membranes were incubated with HRP-conjugated sec-
ondary antibody (1:5000, goat anti-mouse IgG, Cat. No.
GE9542222, Pierce, USA), immunoproducts of b-actin
were developed on a film. The optical density of each
protein band was quantified by a scanning densitometer
and Quantity One Software, version 4.4.1 (Bio-Rad, CA,
USA). Each lane of protein band density was normalized
with corresponding b-actin density.
Real time reverse-transcription polymerase chain
reactions (RT-PCR)
Total RNA was extracted from frozen corpus callosum or
primary culture microglia using RNeasy Mini kit (Qiagen,
Valencia, CA, USA) and its concentration was quantified
with a biophotometer (Eppendorf, Westbury, NY, USA).
Reverse transcription was carried out as follows: A mix-
ture of 2 μg total RNA and 2 μl Oligo (dT) was heated at
70 °C for 5 min, rapidly cooled down on ice and mixed
with reaction mixture containing 5 μl M-MLV RT 5X
Buffer (Cat. No M531A, Promega, USA), 0.5 μl deoxyri-
bonucleotide triphosphate (dNTP, 25 μM, Cat No.
U1240, Promega, USA), 0.7 μl RNAse inhibitor (2500U,
RNasin® Cat. No N211A, Promega, USA) and 1 μl
M-MLV reverse transcriptase (10000u; Cat. No M170A,
Promega, USA). The reaction was made up to 25 μl with
RNA-free water and then incubated at 42 °C for 1 h and
at 70 °C for 10 min. cDNA was synthesized and stored at
-80°C until its use. RT-PCR was carried out on a Light-
Cycler instrument using QuantiTect SYBR Green PCR
Kit (Cat. No. 204141, QIAGEN, USA) according to the
manufacturer’s instructions. For RT-PCR, reaction mix-
ture containing 5 μl QuantiTect SYBR Green PCR Mas-
ter Mix, 0.5 μl of 10 μM forward primer, 0.5 μl of 10 μM
reverse primer, cDNA template and RNAse-free water
was prepared and transferred into capillary glass tubes.
PCR was performed under the following conditions:
denaturation at 95 °C for 15 min, followed by 45 cycles of
denaturation at 94 °C for 15 s, annealing at 61 °C for 22 s,
and extension at 72 °C for 30 s.
Expression of target genes was measured in triplicate
and was normalized to b- actin, an internal control. The
RT-PCR products were subjected to 2% agarose gel elec-
trophoresis, stained with 1mg/mL ethidium bromide,
and photographed using ChemiGenius2 image analyzer
(SYNGENE, Cambridge, UK). Forward and reverse pri-
mer sequences for each gene and their corresponding
amplicon sizes are provided in Table 1. The predicted
size and single band confirmed the amplicons and that
the respective primers were specific. Fold change of
Table 1 Primer sequences used for RT-PCR
Name Forward Reverse Size
(bp)
TNF-a ccaacaaggaggagaagttcc ctctgcttggtggtttgctac 134
IL-1b ggaacccgtgtcttcctaaag ctgacttggcagaggacaaag 123
SphK1 tcagtctgtcctggggtttc tcctccagaggaacgaggta 226
b- actin tcatgaagtgacgttgacatccgt cctagaagcatttgcggtgcaggatg 285
Lin et al. Journal of Neuroinflammation 2011, 8:13
http://www.jneuroinflammation.com/content/8/1/13
Page 3 of 24
Figure 1 Confocal images showing SphK1 immunoexpression in OX-42 positive amoeboid microglial cells in different age groups.
Coronal sections through the forebrain of rats aged 1, 3, 5, 7 and 14 d, showing OX-42 (Aa-Ea) and SphK1 (Ab-Eb) expression in amoeboid
microglial cells (AMC) in the corpus callosum. SphK1 immunofluorescence is detected in AMC (Ab, Bb, Cb, Db) as confirmed by OX-42 labeling
(Aa, Ba, Ca, Da). Co-expression of OX-42 and SphK1 is seen in merged images in Ac, Bc, Cc and Dc (yellow, white arrows). SphK1
immunofluorescence is evident in AMC in rats aged 1, 3 and 5 d but appears to be weaker at age 7 d; it is absent in 14-d-old rats (Ea-c). Nuclei
are stained with DAPI. Scale bar = 50 μm.
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Figure 2 Isotypic control for SphK1 immunoreactivity. Sections incubated with rabbit IgG as an isotypic control for anti-SphK1 do not show
any immunoreactivity, confirming the specificity of SphK1 immunoreactivity (Aa-c). Nuclei of all cells are stained with DAPI. Quantitative analysis
shows that the frequency of SphK1-positive AMC decreases progressively with advancing age. The majority of AMC in 1-5-d-old rats are SphK1
positive. The number of SphK1-positive cells decreased by age 7-14 d (B). Likewise, SphK1 immunofluorescence intensity is attenuated with
advancing age (C). Scale bar = 50 μm.
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Figure 3 SphK1 immunoexpression (Ab, Bb, Cb, Db) and OX-42 immunoexpression (Aa, Ba, Ca, Da) in AMC in the corpus callosum of
5-d-old rats given saline and LPS injection and sacrificed at 30 min, 1 h and 6 h. SphK1 (Bb, Cb, Db) immunoexpression is increased after
LPS injection compared with rats given saline injection (Aa - Ac). Panels Ac, Bc, Cc, Dc show co-expression of OX-42 and SphK1 in AMC (arrows)
stained with nuclear DAPI. Scale bar = 50 μm.
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Figure 4 Quantitative analysis of number, intensity and mRNA expression of SphK1 positive AMC. The number of SphK1-positive AMC
(co-expressing OX-42) is increased 1 h after LPS injection (A). The intensity of SphK1 immunofluorescence is also increased significantly at 30
min to 1 h compared with that 6 h after LPS injection and that of control (B). SphK1 mRNA expression (C) is detected in primary microglial cells
in vitro and its expression was induced significantly in cells exposed to LPS for 1 h, as revealed by RT-PCR (D) The data are normalized with the
housekeeping gene, b-actin (C) and presented as mean ± S.E. Control vs LPS, * P < 0.05, ** P < 0.01.,*** P < 0.001.
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target genes’ expression was calculated according to the
formula: fold change = 2-[[Ct (control) gene X-Ct (control)
actin]-[Ct (activated) gene X-Ct (activated) actin]] [28].
Primary culture of microglial cells
Mixed glial cells were prepared from the cerebrum in
neonatal rats aged 3 days and cultured in a flask contain-
ing Dulbecco’s modified Eagle’s medium (DMEM), 10%
fetal bovine serum (FBS), 10 ml/L antibiotic-anti-mycotic
(Cat. No. A5955, Sigma, USA), 0.1 mM nonessential
amino acid (Cat. No. 11140-050, Invitrogen, USA) and 1
ml/L insulin (Cat. No. I-0516, Sigma, USA). The com-
plete medium was replaced at 24 h and then every
3-4 days. Microglial cells were isolated at 10 days with
0.25% trypsin including 1 mM ethylene diamine tetra
acetic acid (EDTA) for 10-20 min at 37 °C[29]. With a
complete detachment of upper cell layer, microglial cells
remained attached to the bottom of the flask and DMEM
containing 10% FBS was added for trypsin inactivation.
Microglial cells were cultured in complete medium over-
night for their identification. The purity of microglial
cells was confirmed by OX-42 labeling.
Immunofluoresence staining of cultured microglial cells
Microglial cells were plated on poly-L-lysine coated cov-
erslips and cultured in complete medium overnight. The
complete medium was then replaced by basic medium
and LPS (1 μg/mL) was added into the basic medium
for 1 h with or without pretreatment of DMS (15 μM,
15 min). Cells cultured in the basic medium served as
the control. The cells were then rinsed with PBS and
fixed with 4% paraformaldehyde in phosphate buffer for
30 min at room temperature. Following incubation in
normal goat serum, all coverslips with adherent cells
were incubated in a mixture of antibodies containing
anti-SphK1 (1:100, Santa Cruz, USA) and OX-42 (1:200,
Chemicon, USA) at 4°C overnight. The coverslips
were washed and incubated with Cy3-conjugated goat
anti-rabbit IgG (1:100, Chemicon, USA) and FITC-
conjugated goat anti-mouse IgG (1:100, Chemicon,
USA) for 1 h at room temperature. Cell nuclei were
counterstained with DAPI (1 μg/mL) for 2 min. The
coverslips were then washed and mounted with a fluor-
escent mounting medium (DAKO Cytomation,
Glostrup, Denmark). All images were captured under a
confocal microscope (LSM FV1000; Olympus Company
Pte. Ltd., Tokyo, Japan).
Quantitative immunofluorescence analysis of microglial
cells
Immunofluorescence staining of SphK1, IL-1b, TNF-a
and NFB in microglial cells was digitally captured by
using a confocal microscope, and the average intensity
of immunofluorescence in microglial cells was estimated
using a software system (Fluoview, FV1000). Background
(nonspecific extracellular signal) was optimized. These
settings, used to optimize image quality, were then
applied as standards for the processing of all cell images.
Between seven and ten intact microglial cells (showing
cellular and nuclear integrity) from each slide were
selected and specified by drawing outlines, and their
images were acquired in a single channel (showing sin-
gle colour). The mean value of the intensity in the spe-
cified region was measured and normalized with the
intensity value obtained from isotypic control sections.
Fold changes were calculated and presented in a histo-
gram. The total number of microglial cells on each slide
was manually counted in a specified unit area. The per-
centages of SphK1-, IL-1b-, TNF-a-, and NFB-positive
cells were also calculated by counting the number of
positive cells in OX-42-stained microglia.
Results
SphK1 immunoexpression in amoeboid microglial cells
varies with age in normal rats
AMC in the corpus callosum at different age groups was
found to show moderate but definite expression of SphK1
protein as revealed by immunofluorescence staining (Fig-
ure 1Aa-Dc, Figure 2B, C). The identification of SphK1-
immunoreactive AMC was confirmed by their colocaliza-
tion with OX42 immunofluorescence. Sections incubated
with rabbit IgG as the isotypic control for anti-SphK1 did
not show any immunoreactivity, confirming the specificity
of SphK1 immunoreactivity (Figure 2Aa-c). The intensity
of SphK1 expression in AMC was most intense in corpus
callosum of 1- to 5-day-old rats compared to that of those
aged 7 d (Figure 1Da-c, Figure 2C). In rats aged 14 d (Fig-
ure 1Ea-c, Figure 2C) and 21 d (data not shown), in which
microglia had assumed a ramified shape, SphK1 immuno-
fluorescence was undetectable. Quantitative analysis
revealed that the number of SphK1-positive AMC was
more numerous in corpus callosum of 1-5 d rats than that
of 7-14 d rats (Figure 2B).
LPS and hypoxia upregulate SphK1 expression in AMC
In 5-d-old rats injected with LPS, the incidence of
SphK1-immunopositive AMC as well as SphK1 immu-
noreactivity in corpus callosum was increased compared
to that of corresponding control rats with saline injec-
tion (Figure 3Aa-Dc, Figure 4A, B). The number of
SphK1-positive AMC (co-expressing OX-42) was found
to be significantly increased at 1 h compared with that
at 30 min or 6 h after LPS injection and that of controls
(Figure 3Ba-c, Ca-c, Da-c, Figure 4A). The intensity of
SphK1 immunofluorescence was found to be increased
significantly at 30 min to 1 h compared with that 6 h
after LPS injection and that of controls (Figure 4B).
Further, mRNA expression of SphK1 (Figure 4C) was
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detected in primary microglial cells in vitro and its
expression was induced significantly in cells exposed to
LPS for 1 h (Figure 4D).
In rats subjected to hypoxic exposure, SphK1 immunoex-
pression in AMC was drastically increased (Figure 5A-D,
Figure 6A). Virtually all OX-42-positive AMC exhibited
more intense SphK1 immunofluorescence 1 h after
hypoxia, compared with that in control rats (Figure 5Ca-c,
Figure 6A). At 6 h after hypoxia, SphK1 immunofluores-
cence in AMC appeared to be diminished, although OX-
Figure 5 OX-42 and SphK1 expression in AMC in the corpus callosum of 5-d-old rats subjected to hypoxia for 2 h and sacrificed at
15 min, 1 and 6 h. OX-42 and SphK1 expression is noticeably increased after hypoxia (Ba-b, Ca-b, Da-b) compared with that in control (Aa-b).
Co-expression is seen in merged images in Ac, Bc, Cc and Dc (arrows). Note that SphK1 expression is most intense at 1 h (Cc). Nuclei are stained
with DAPI. Scale bar = 50 μm.
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42 immunofluorescence in AMC remained intense and
the cells were hypertrophic (Figure 5Da-c).
DMS inhibits SphK1 expression in amoeboid microglial cells
As mentioned previously, LPS upregulated SphK1 mRNA
and protein expression in AMC of corpus callosum
(Figure 7). However, injection of DMS prior to LPS evi-
dently suppressed LPS-induced SphK1 expression in
AMC as manifested by its reduced immunofluorescence
staining and mRNA expression (Figure 7A-D, Figure 8A-C).
A similar phenomenon was observed in microglial cell cul-
tures treated with LPS and DMS + LPS when compared
Figure 6 Quantitative analysis of number and intensity of SphK1 positive AMC. Significantly increased numbers of SphK1-positive AMC
(co-expressing OX-42) are evident in 1 h after hypoxia (A). The intensity of SphK1 immunofluorescence is increased significantly at 15 min and 1 h
compared with that 6 h after hypoxia and that of control (B). The data are presented as mean ± S.E. Control vs Hypoxia, * P < 0.05, ** P < 0.01.
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Figure 7 SphK1 (Ab Bb, Cb, Db) expression in 5-d-old rats receiving saline, DMS, LPS or DMS + LPS injection, and sacrificed 1 h later.
Immunofluorescence analysis reveals colocalization of OX-42 (Aa, Ba, Ca, Da) and SphK1 (Ab, Bb, Cb, Db) in AMC of corpus callosum as shown in
the merged images (Ac, Bc, Cc, Dc). The intensity of SphK1 expression in AMC is clearly enhanced after LPS injection (Cb) when compared with
that of the control (Ab) and DMS (Bb) groups (arrows). In rats treated with either DMS alone or DMS + LPS, SphK1 immunofluorescence
intensity in AMC appears to be unchanged (Bb, Db). Nuclei are stained with DAPI. Scale bar = 50 μm.
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Figure 8 Levels of SphK1 mRNA expression and immunofluorescence intensity and the number of SphK1 positive cells are reduced
after LPS and DMS treatments. RT-PCR analysis demonstrates that SphK1 mRNA expression is increased more than 25 fold in corpus callosum
of rats injected with LPS, and the concomitant injection of DMS prevented this increase of SphK1 (A). Injection of DMS alone did not have any
effect on SphK1 mRNA expression. Quantitative analysis shows that the number of SphK1-positive AMC decreased in rats injected with DMS
+LPS, when compared to that in rats injected with LPS alone (B), Further, the intensity of SphK1 immunofluorescence was also decreased in rats
injected with DMS+LPS when compared to that in rats injected with LPS alone (C). Data are presented as mean ± S.E. * vs control, * P < 0.05,
** P < 0.01, *** P < 0.001 Scale bar = 50 μm.
Lin et al. Journal of Neuroinflammation 2011, 8:13
http://www.jneuroinflammation.com/content/8/1/13
Page 12 of 24
Figure 9 SphK1 immunoexpression in AMC after LPS and DMS treatments (Aa-c). The cells treated with LPS (Ba-c) appear hypertrophic
(arrows) and exhibit enhanced SphK1 immunoexpression (Bb) as evident in the merged image (Bc). In cells treated with DMS alone or with
DMS + LPS (Ca-c, Da-c), the intensity of SphK1 expression appears to be unaltered, compared to that of control (Aa-c). Nuclei are stained with
DAPI. Scale bar = 50 μm.
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Figure 10 Number, intensity and protein expression in SphK1 positive cells after LPS and DMS treatments. Quantitative analysis shows
that the number of SphK1-positive AMC increased in cultures treated with LPS when compared to that in untreated cultures (A). This increase in
number was not evident in cultures treated with DMS alone or DMS+LPS. Quantitative analysis reveals that the intensity of SphK1
immunofluorescence is increased in cultures treated with LPS when compared to that of untreated cultures (B). Western blot analysis of SphK1
protein levels in the corpus callosum of rats 1 h after LPS or DMS+LPS injection, and corresponding saline controls has been carried out (C, D).
C, SphK1 (43kDa) and b-actin (43kDa) immunoreactive bands are shown. D, The optical density of SphK1 following LPS treatment is significantly
increased when compared with the corresponding controls. Note that concomitant injection of DMS with LPS did not increase SphK1 protein
levels (** p < 0.01, ΔΔ p < 0.01). All experiments were carried out in triplicate.
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with corresponding controls (Figure 9A-D, Figure 10A, B).
The suppression of SphK1 by DMS pretreatment was
corroborated by western blot analysis (Figure 10C,D) and
RT-PCR (Figure 8A). DMS alone had no significant effect
on the expression of SphK1 (Figure 7B, 9C) and this was
confirmed by RT-PCR (Figure 8A). LPS-induced TNF-a
immunofluorescence intensity (Figure 11C, Figure 12A,B)
was found to be reduced in AMC after DMS pretreatment
and there was no marked change in LPS-induced IL-1b
(Figure 13C, Figure 14A,B) immunofluorescence intensity
in those cells. However, real time RT-PCR analysis showed
that LPS-induced TNF-a and IL-1b mRNA expression
was suppressed in primary culture microglia treated with
DMS prior to LPS (Figure 12C and Figure 14C). On the
other hand, the intensity of NFB immunoexpression in
AMC found in corpus callosum was significantly increased
Figure 11 OX-42 (Aa, Ba, Ca) and TNF-a (Ab, Bb, Cb) expression in 5-d-old rats receiving saline, LPS or DMS + LPS injection and
sacrificed 1 h later. The intensity of TNF-a immunoexpression in AMC is evidently augmented after LPS injection (Bb) when compared with
that in the saline group (Ab) (arrows). This is more evident in merged images in Bc in comparison with Ac. In rats treated with DMS + LPS (Ca-
c), TNF-a expression appears to be significantly reduced as shown by its co-localization with OX-42 in AMC (Ca-c). Nuclei are stained with DAPI.
Scale bar = 50 μm.
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Figure 12 Number, intensity and mRNA expression in TNF-a-positive AMC after different treatments. Quantitative analysis shows that
the number of TNF-a-positive AMC decreased in rats injected with DMS+LPS when compared to that in rats injected with LPS alone (A). The
intensity of TNF-a immunofluorescence is decreased in rats injected with DMS+LPS when compared to that in rats injected with LPS alone (B).
RT-PCR analysis demonstrates that TNF-a mRNA expression is increased about 50 fold in primary microglial cells in vitro treated with LPS, and
that concomitant treatment with DMS prevented this increase in TNF-a (C). Data are presented as mean ± S.E, Control vs LPS, **P < 0.01.
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at 1 h after LPS injection, and NFB immunofluorescence
colocalized with OX-42 (Figure 15Aa-Cc, Figure 16B).
Moreover, nuclear translocation of NFB appeared to be
more evident in those cells (Figure 15Bb, Figure 16A).
Pretreatment of rats with DMS reduced the incidence of
OX-42-labeled, NFB-immunopositive AMC and NFB
nuclear translocation (Figure 15C). In vitro analysis using pri-
mary cultures of microglia also showed that LPS treatment
induced NFB translocation from cytoplasm to the nucleus
(Figure 17Ba-Bc). This translocation of NFB was reversed in
activated cells pretreated with DMS (Figure 17Da-Dc).
Discussion
SphK1 is a key enzyme in the sphingolipid metabolic
pathway, phosphorylating sphingosine into S1P and
regulating intracellular levels of S1P. The SphK1
Figure 13 OX-42 (Aa, Ba, Ca) and IL-1b (Ab, Bb, Cb) expression in 5-d-old rats receiving saline, LPS or DMS + LPS injections and
sacrificed 1 h later. The intensity of IL-1b immunoexpression in AMC is significantly enhanced in LPS-injected rats (Ba-c) when compared with
control rats (Aa). Upregulated IL-1b immunoexpression in AMC appears to be sustained in DMS + LPS-injected rats (Ca). Co-expression of OX-42
and IL-1b is evident in DMS + LPS rats as seen in merged images in Cc (arrows). Nuclei are stained with DAPI. Scale bar = 50 μm.
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Figure 14 Number, intensity and mRNA expression in IL-1b-positive AMC after different treatments. Quantitative analysis shows that
there is a significant reduction in the number of IL-1b-positive AMC in rats injected with DMS+LPS when compared to that in rats injected with
LPS alone (A). Further, the intensity of IL-1b immunofluorescence is decreased in rats injected with DMS+LPS when compared to that in rats
injected with LPS alone (B). RT-PCR analysis demonstrates that IL-1b mRNA expression is increased significantly in primary microglial cells in vitro
treated with LPS, and that concomitant treatment with DMS prevented this increase in IL-1b (C). Data are presented as mean ± S.E, Control vs
LPS, ** P < 0.01.
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signaling pathway is involved in cell proliferation, sur-
vival, apoptosis, and cell growth arrest as well as regu-
lation of proinflammatory cytokines [30-35]. It has
been reported that SphK1 is distributed in rat cerebel-
lum, cerebral cortex, brainstem, striatum and hippo-
campus; and that SphK1 is a dominant contributor to
total SphK activity in mouse brain [36,37]. The present
study has shown expression of SphK1 in AMC in cor-
pus callosum of postnatal rat brain in vivo as well as
in primary microglia in vitro. Since SphK1 is constitu-
tively expressed in AMC, it is justified to suggest that
this enzyme is linked to normal physiological functions
Figure 15 OX-42 (Aa, Ba, Ca) and NFkB (Ab, Bb, Cb) expression in 5-d-old rats receiving saline, LPS or DMS + LPS injection and
sacrificed 1 h later. NFkB immunoexpression in AMC found in corpus callosum is clearly enhanced in LPS-injected rats (Ba-c) when compared
with control rats (Aa-c). Decreased NFkB immunoexpression in AMC is observed in DMS + LPS-injected rats (Ca-c). Co-expression of OX-42 and
NFkB is evident in merged images in Ac, Bc and Cc (arrows). Moreover, nuclear translocation of NFB appears to be more evident and
significantly increased in AMC of LPS-injected rats (Bb) when compared with that of control rats or rats injected with LPS+DMS (Fig. Ab, Cb).
Nuclei are stained with DAPI. Scale bar = 20 μm.
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of cells in developing brain. The progressive reduction
of SphK1 expression in AMC with advancing age indi-
cates its diminishing role in the developing corpus cal-
losum over a time period wherein it has been reported
that all AMC transform at the 14th postnatal day into
a more mature form, namely, ramified microglia that
have been considered to be the resting form of micro-
glia in the adult brain [18]. It is interesting to note
that resting cells typically have very low levels of
sphingolipid metabolities, including SphK1 [38].
Figure 16 Quantitative analysis shows that the nuclear translocation and intensity of NFB immunostaining is significantly increased
in AMC of LPS-injected rats when compared with that of control rats or rats injected with LPS+DMS (A,B). Data are presented as mean
± S.E, Control vs LPS, * P < 0.05.
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Figure 17 NFB expression in primary cultures of AMC labeled by OX-42. NFkB immunoexpression is clearly enhanced in primary culture
microglia exposed to LPS (Ba-c) when compared with control AMC (Aa-c). Decreased NFkB immunoexpression in AMC is observed in AMC
treated with either DMS alone (Ca-c) or DMS + LPS (Da-c). Co-expression of OX-42 and NFkB is evident in cells as seen in merged images
(arrows).Moreover the nuclear translocation of NFB appears to be more evident in LPS-treated cells compared with control and DMS + LPS
treated cells. Nuclei are stained with DAPI. Scale bar = 20 μm.
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It is well documented that microglia have been recog-
nized as gatekeepers of CNS diseases and immunology
[39] and that microglial cells activated by LPS, by
hypoxia, or by neurodegenerative diseases produce
increased amounts of proinflammatory cytokines such
as TNF-a and IL-1b in the CNS [40-43]. SphK1 partici-
pates in inflammatory responses such as TNF-a secre-
tion [31,44,45] and production of cytokines, and
blockade of SphK1 activity suppresses such responses in
peripheral macrophages and murine BV2 cells
[5,13,20,46]. The present results have shown that SphK1
expression in AMC is greatly enhanced by LPS or
hypoxia treatment. It is noteworthy that SphK1 immu-
noexpression was most intense at 1 h after either LPS
or hypoxia treatment indicating its early onset of induc-
tion and crucial role in the early stage of inflammation
in CNS. This is in accordance with the observation that
SphK1 expression is induced by LPS in murine macro-
phages and BV2 cells [5,35]. It is striking that LPS- or
hypoxia-induced SphK1 expression in AMC returned to
basal levels, suggesting its reversible and transient nat-
ure. That LPS and hypoxia could induce upregulated
expression of SphK1 in AMC is further supported by
the increased level of SphK1 protein in corpus callosum
containing a large number of AMC.
Further, reduced SphK1 expression in AMC was evi-
dent in postnatal rats treated with DMS, a pharmaco-
logical inhibitor of SphK1. A similar phenomenon was
observed in primary microglial cultures when com-
pared with that in matching controls. The swift
response and upregulation of SphK1 expression in
AMC treated with LPS or hypoxia suggests the invol-
vement of the enzyme in an early stage of inflamma-
tion. This is further supported by in vitro analysis
which showed suppression of LPS-induced TNF-a,
and IL-1b mRNA expression in primary culture
microglia and in BV2 cells treated with DMS [5].
However, pretreatment of LPS-injected postnatal rats
with DMS in vivo did not alter the expression of all
proinflammatory cytokines. For example, there was no
marked change in IL-1b protein expression in AMC of
corpus callosum as revealed by immunoflurescence.
One possible explanation for this discrepancy may be
that the dosage of DMS used might not be potent
enough to suppress LPS-induced IL-1b expression in
vivo . We have also shown here that LPS-induced
SphK1 and NFB immunoexpression in AMC is sup-
pressed by DMS. It has been reported that SphK1 is
involved in LPS-induced NFB activation, and that
DMS can block LPS-stimulated NFB activiation [35].
Since DMS appears to act by suppressing protein
kinase C, which upregulates the activity of both
isoforms of SphK1 and SphK2 [47,48], further studies
using SphK1-null mice may be required to confirm
the involvement of SphK1 in microglial activation in
neuroinflammation.
Notwithstanding the above, it is unequivocal from
the present results that AMC in the developing brain
constitutively express SphK1 which can be upregulated
by LPS and hypoxic exposure. The expression of S1P1-
3, 5 receptors in AMC (data not shown) suggests that
SphK1-S1P pathway operates in AMC and that it may
be linked to local neuroinflammation. An example of
the latter is periventricular white matter damage in
hypoxia, in which AMC are involved through increased
release of TNF-a and IL-1b [21]. On the other hand,
the interrelations between SphK1 and the above-men-
tioned various factors and pathways obviously remain
complex and await further elucidation. In view of the
fact that DMS reduces SphK1 expression in AMC and
BV2 cells [5], and that NFB expression is SphK1
dependent [35], SphK1 appears to be a potential thera-
peutic target for ameliorating microglia-mediated
neuroinflammation.
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